Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer
Cediranib–olaparib combination is effective regardless of disease mutations
Results from the BAROCCO trial may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer
Ceritinib demonstrates efficacy in brain metastases in ALK+ NSCLC
Results from ASCEND-7 trial confirms the place of ceritinib as a standard treatment option for patients with ALK+ non-small-cell lung cancer and active brain metastases
Over one hundred ESMO research fellows in 30 years
2019 marks the 30th Anniversary of the ESMO Fellowship Programme, a programme that has provided many young oncologists valuable educational opportunities, shaped professional lives and enhanced careers
From research bench to the patient’s bedside
ESMO Congress 2019 held in Barcelona, Spain, from 27 September to 1 October 2019
Adding FOLFIRINOX to nab-PG may improve outcomes in pancreatic cancer
Results from the phase II NEOLAP study presented at ESMO 2019